KR102874711B1 - 전장 고분자량 키니노겐(hmwk) 및 절단된 hmwk를 구별하기 위한 펩타이드 정량화 검정법 - Google Patents

전장 고분자량 키니노겐(hmwk) 및 절단된 hmwk를 구별하기 위한 펩타이드 정량화 검정법

Info

Publication number
KR102874711B1
KR102874711B1 KR1020247036874A KR20247036874A KR102874711B1 KR 102874711 B1 KR102874711 B1 KR 102874711B1 KR 1020247036874 A KR1020247036874 A KR 1020247036874A KR 20247036874 A KR20247036874 A KR 20247036874A KR 102874711 B1 KR102874711 B1 KR 102874711B1
Authority
KR
South Korea
Prior art keywords
hmwk
peptide
seq
glu
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020247036874A
Other languages
English (en)
Korean (ko)
Other versions
KR20240161708A (ko
Inventor
지앙 우
궈동 장
다니엘 제이. 섹스톤
라이언 파우셋
굴 엠. 무사타파
마크 즈젝
Original Assignee
다케다 파머수티컬 컴패니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다케다 파머수티컬 컴패니 리미티드 filed Critical 다케다 파머수티컬 컴패니 리미티드
Publication of KR20240161708A publication Critical patent/KR20240161708A/ko
Application granted granted Critical
Publication of KR102874711B1 publication Critical patent/KR102874711B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/62Detectors specially adapted therefor
    • G01N30/72Mass spectrometers
    • G01N30/7233Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/88Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848Methods of protein analysis involving mass spectrometry
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N2030/022Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027Liquid chromatography
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/88Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00Chemical aspects of mass spectrometric analysis of biological material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/22Haematology
    • G01N2800/224Haemostasis or coagulation
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020247036874A 2015-12-15 2016-12-15 전장 고분자량 키니노겐(hmwk) 및 절단된 hmwk를 구별하기 위한 펩타이드 정량화 검정법 Active KR102874711B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562267734P 2015-12-15 2015-12-15
US62/267,734 2015-12-15
PCT/US2016/066936 WO2017106504A1 (en) 2015-12-15 2016-12-15 Peptide quantitation assay for differentiating full-length high molecular weight kininogen (hmwk) and cleaved hmwk
KR1020187020049A KR102728491B1 (ko) 2015-12-15 2016-12-15 전장 고분자량 키니노겐(hmwk) 및 절단된 hmwk를 구별하기 위한 펩타이드 정량화 검정법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187020049A Division KR102728491B1 (ko) 2015-12-15 2016-12-15 전장 고분자량 키니노겐(hmwk) 및 절단된 hmwk를 구별하기 위한 펩타이드 정량화 검정법

Publications (2)

Publication Number Publication Date
KR20240161708A KR20240161708A (ko) 2024-11-12
KR102874711B1 true KR102874711B1 (ko) 2025-10-23

Family

ID=57794352

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020247036874A Active KR102874711B1 (ko) 2015-12-15 2016-12-15 전장 고분자량 키니노겐(hmwk) 및 절단된 hmwk를 구별하기 위한 펩타이드 정량화 검정법
KR1020187020049A Active KR102728491B1 (ko) 2015-12-15 2016-12-15 전장 고분자량 키니노겐(hmwk) 및 절단된 hmwk를 구별하기 위한 펩타이드 정량화 검정법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187020049A Active KR102728491B1 (ko) 2015-12-15 2016-12-15 전장 고분자량 키니노겐(hmwk) 및 절단된 hmwk를 구별하기 위한 펩타이드 정량화 검정법

Country Status (13)

Country Link
US (3) US11668718B2 (https=)
EP (2) EP3390439B1 (https=)
JP (4) JP7092669B2 (https=)
KR (2) KR102874711B1 (https=)
CN (1) CN108602877A (https=)
AU (3) AU2016372159B2 (https=)
CA (1) CA3008621A1 (https=)
CO (1) CO2018007216A2 (https=)
EA (1) EA201891414A1 (https=)
IL (4) IL297850B2 (https=)
MX (2) MX2018007493A (https=)
NZ (1) NZ743482A (https=)
WO (1) WO2017106504A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2927695C (en) 2013-10-21 2022-03-01 Dyax Corp. Diagnosis and treatment of autoimmune diseases
WO2015061183A1 (en) 2013-10-21 2015-04-30 Dyax Corp. Assays for determining plasma kallikrein system biomarkers
EP4354146B1 (en) 2015-10-19 2026-04-15 Takeda Pharmaceutical Company Limited Immunoassay for the detection of cleaved high molecular weight kininogen
KR102874711B1 (ko) 2015-12-15 2025-10-23 다케다 파머수티컬 컴패니 리미티드 전장 고분자량 키니노겐(hmwk) 및 절단된 hmwk를 구별하기 위한 펩타이드 정량화 검정법
WO2018225830A1 (ja) * 2017-06-08 2018-12-13 国立大学法人宮崎大学 肺がんの検出方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047323A (en) 1986-01-22 1991-09-10 Temple University Of The Commonwealth System Of Higher Education Method for detecting human kininogen using monoclonal antibodies thereto
JP2603487B2 (ja) 1987-11-26 1997-04-23 大日本製薬株式会社 ガンに罹患している疑いのあるヒトをスクリーニングする方法
JPH08208692A (ja) 1994-09-28 1996-08-13 Sumitomo Pharmaceut Co Ltd 新規な細胞接着抑制ペプチド誘導体
JP3073439B2 (ja) * 1996-02-08 2000-08-07 雪印乳業株式会社 骨形成促進及び骨吸収防止剤
AU1521500A (en) 1998-11-10 2000-05-29 W. Robert Colman Inhibition of angiogenesis by peptide analogs of high molecular weight kininogendomain
US20060154319A1 (en) 1999-04-29 2006-07-13 Flodgaard Hans J Inhibition of bradykinin release
WO2001034195A1 (en) 1999-11-12 2001-05-17 Temple University Of The Commonwealth System Of Higher Education Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5
EP1575525A4 (en) 2002-03-15 2008-04-02 Attenuon Llc CELL SURFACE TROPOMYOSIN AS A TARGET FOR THE INHIBITION OF ANGIOGENESIS
CN1858243A (zh) 2005-04-30 2006-11-08 安徽省生物医学研究所 一种预测血管紧张素ii受体拮抗剂类降压药药物作用的方法及其应用
US8263347B2 (en) 2007-10-18 2012-09-11 Miyazaki Prefectural Industrial Support Foundation Biomarker for diagnosis of liver disease
CA2729937A1 (en) * 2008-07-07 2010-01-14 Nippon Zoki Pharmaceutical Co., Ltd. Fibromyalgia test method
GB0821721D0 (en) 2008-11-27 2008-12-31 Hansa Medical Ab Antimicrobial therapy
EP2770327B1 (en) 2009-03-30 2017-06-14 Nordic Bioscience A/S Fibrosis biomarker assay
JP5714285B2 (ja) * 2010-09-29 2015-05-07 株式会社プロトセラ 妊娠高血圧症候群マーカーおよびそれを用いた診断
CN102558329A (zh) 2010-12-10 2012-07-11 中国人民解放军军事医学科学院生物医学分析中心 一组特异性多肽及其在制备肺癌早期诊断试剂中的用途
HUE037720T2 (hu) 2012-03-28 2018-09-28 Sanofi Sa Bradikinin B1 receptor ligandumok elleni antitestek
EP4234583A3 (en) * 2013-01-20 2024-01-24 Takeda Pharmaceutical Company Limited Evaluation and treatment of bradykinin-mediated disorders
JP2016188761A (ja) 2013-08-23 2016-11-04 国立研究開発法人国立国際医療研究センター 糖尿病腎症の発症または発症リスクの検出方法及びキット
WO2015061183A1 (en) * 2013-10-21 2015-04-30 Dyax Corp. Assays for determining plasma kallikrein system biomarkers
WO2015120036A1 (en) * 2014-02-04 2015-08-13 University Of Virginia Patent Foundation Compositions and methods for analysis of protein sequences and post-translational modifications
CN104155457B (zh) 2014-08-22 2016-11-16 北京蛋白质组研究中心 一种结直肠癌相关“多肽-蛋白组合式标志物”检测试剂盒
CN104345154B (zh) 2014-08-22 2016-10-26 北京蛋白质组研究中心 一种检测多肿瘤相关“多肽-蛋白组合式标志物”的双抗体夹心试剂盒
WO2016081413A1 (en) * 2014-11-17 2016-05-26 The Rockefeller University Compositions and methods for use in diagnosis of alzheimer's disease
KR102874711B1 (ko) 2015-12-15 2025-10-23 다케다 파머수티컬 컴패니 리미티드 전장 고분자량 키니노겐(hmwk) 및 절단된 hmwk를 구별하기 위한 펩타이드 정량화 검정법

Also Published As

Publication number Publication date
BR112018012165A2 (pt) 2018-12-04
IL312919A (en) 2024-07-01
IL259995B1 (en) 2023-01-01
MX2023000773A (es) 2023-02-22
AU2022204058A1 (en) 2022-06-30
CN108602877A (zh) 2018-09-28
JP7425117B2 (ja) 2024-01-30
KR20240161708A (ko) 2024-11-12
EP4597115A2 (en) 2025-08-06
JP2025188193A (ja) 2025-12-25
CO2018007216A2 (es) 2018-09-20
AU2016372159B2 (en) 2022-03-24
EP4597115A3 (en) 2025-08-13
NZ743482A (en) 2023-04-28
EP3390439A1 (en) 2018-10-24
US20250172567A1 (en) 2025-05-29
WO2017106504A1 (en) 2017-06-22
WO2017106504A8 (en) 2017-07-13
JP2022141640A (ja) 2022-09-29
MX2018007493A (es) 2018-09-18
IL312919B1 (en) 2025-10-01
US12135329B2 (en) 2024-11-05
JP2024026847A (ja) 2024-02-28
JP7092669B2 (ja) 2022-06-28
US20230408528A1 (en) 2023-12-21
AU2025200412A1 (en) 2025-02-13
AU2016372159A1 (en) 2018-07-05
EA201891414A1 (ru) 2019-02-28
JP7758766B2 (ja) 2025-10-22
KR20180134838A (ko) 2018-12-19
IL297850B1 (en) 2024-06-01
IL259995A (en) 2018-07-31
US11668718B2 (en) 2023-06-06
IL312919B2 (en) 2026-02-01
KR102728491B1 (ko) 2024-11-13
IL322971A (en) 2025-10-01
IL259995B2 (en) 2023-05-01
IL297850B2 (en) 2024-10-01
EP3390439B1 (en) 2025-03-12
JP2019505185A (ja) 2019-02-28
AU2022204058B2 (en) 2024-10-31
US20210025898A1 (en) 2021-01-28
IL297850A (en) 2023-01-01
CA3008621A1 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
JP7425117B2 (ja) 完全長の高分子量キニノーゲン(hmwk)と切断されたhmwkとを区別するためのペプチド定量アッセイ
Kalita et al. Quantitative proteomic analysis and antivenom study revealing that neurotoxic phospholipase A2 enzymes, the major toxin class of Russell's viper venom from southern India, shows the least immuno-recognition and neutralization by commercial polyvalent antivenom
JP2023078232A (ja) 接触系活性化の評価のためのプロテアーゼ阻害剤を含む真空採血管
Snipsøyr et al. Towards identification of novel putative biomarkers for infective endocarditis by serum proteomic analysis
KR102869359B1 (ko) 기능성 c1 에스테라제 저해제(fc1-inh)의 정량 방법
CN113287019A (zh) 亚临床动脉粥样硬化的生物标志物
HK40129146A (en) Peptide quantitation assay for differentiating full-length high molecular weight kininogen (hmwk) and cleaved hmwk
Gonzales et al. Development of a specific ELISA to measure BACE1 levels in human tissues
BR112018012165B1 (pt) Método para detectar cininogênio de alto peso molecular (hmwk) clivado, método para diferenciar hmwk completo e hmwk clivado, e método para identificar um sujeito com, ou correndo o risco de ter, angioedema hereditário (hae)
US20240377410A1 (en) Methods for the measurement of protein c and activated protein c
WO2011049442A2 (en) Blood coagulation status measurement in saliva
WO2011143412A1 (en) Methods for the detection and monitoring of acute myocardial infarction
HK40061902B (en) Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
JP2001272396A (ja) 男性の不妊症の検出方法
EA040036B1 (ru) Вакуумные пробирки для сбора крови, содержащие ингибиторы протеазы, для оценки активации контактной системы

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)